Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB226 in Relapsed/Refractory PTCL
NCT03502629Phase 2Unknown
- Sponsor
- Genor Biopharma
- Start
- Jul 2018
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of geptanolimab in peripheral T-cell lymphoma (PTCL), sponsored by Genor Biopharma. Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
geptanolimab
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT03502629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03502629.